Table 1.
Patients’ characteristics of both treatment groups
| Variables | Treatment Groups | ||
|---|---|---|---|
| Sitagliptin add-on Metformin | Empagliflozin add-on Metformin | ||
| n (%)* | n (%)* | ||
| Gender | |||
| Female | 45 (62.5) | 27 (37.5) | |
| Male | 34 (41) | 49 (59) | |
| Diagnosis | |||
| Type 2 Diabetes Mellitus | 51 (58) | 37 (42) | |
| Comorbidities | |||
| Hypertension | 28 (41.8) | 39 (58.2) | |
| IHD | 1 (25) | 3 (75) | |
| Years of Diagnosis | |||
| ≤ 3 | 32 (53.3) | 28 (46.7) | |
| 4–7 | 22 (57.9) | 16 (42.1) | |
| 8–10 | 11 (44) | 14 (56) | |
| > 10 | 12 (40) | 18 (60) | |
| Other Parameters | Mean ± SD | Mean ± SD | |
| Age (years) | 50.2 ± 11.1 | 53.2 ± 9.6 | |
| Systolic BP (mm Hg) | 139.1 ± 21.5 | 135.6 ± 24.7 | |
| Diastolic BP (mm Hg) | 85.3 ± 8.9 | 83.7 ± 10.4 | |
| Baseline HbA1c (%) | 9.5 ± 2 | 9.4 ± 1.5 | |
| Follow-up HbA1c (%) | 7.4 ± 1.5 | 7.6 ± 1.2 | |
| Baseline serum creatinine (mg/dl) | 0.96 ± 0.13 | 1.08 ± 0.24 | |
| Follow-up serum creatinine (mg/dl) | 0.94 ± 0.12 | 1.03 ± 0.2 | |
| Baseline eGFR (mL/min/1.73m2) | 79.8 ± 16.1 | 75.4 ± 23.7 | |
| Follow-up eGFR (mL/min/1.73m2) | 81.9 ± 19.3 | 78.1 ± 23.1 | |
*Row-wise percentages were calculated (total number of patients = 155)
i. n = 76 in Empagliflozin-Metformin group
ii. n = 79 in Sitagliptin-Metformin group